Fresenius Medical Care KGaA
Market Cap
€20.9b
Last Updated
2020/01/23 21:12 UTC
Data Sources
Company Financials +
Executive Summary
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally.
Rewards
Risk Analysis
Snowflake Analysis
Established dividend payer and good value.
Similar Companies
Share Price & News
How has Fresenius Medical Care KGaA's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FME has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
3.7%
FME
1.9%
DE Healthcare
0.5%
DE Market
1 Year Return
13.6%
FME
11.2%
DE Healthcare
15.5%
DE Market
Return vs Industry: FME exceeded the German Healthcare industry which returned 8% over the past year.
Return vs Market: FME underperformed the German Market which returned 17.1% over the past year.
Shareholder returns
| FME | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.7% | 1.9% | 0.5% |
| 30 Day | 7.1% | 1.4% | 1.4% |
| 90 Day | 17.9% | 12.8% | 5.3% |
| 1 Year | 15.5%13.6% | 13.3%11.2% | 19.2%15.5% |
| 3 Year | -4.6%-8.3% | -20.8%-23.7% | 15.7%5.5% |
| 5 Year | 13.0%6.4% | 4.3%-1.5% | 27.3%10.1% |
Price Volatility Vs. Market
How volatile is Fresenius Medical Care KGaA's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Introducing Fresenius Medical Care KGaA (ETR:FME), A Stock That Climbed 12% In The Last Year3 weeks ago | Simply Wall St
Are Fresenius Medical Care AG & Co. KGaA’s (ETR:FME) High Returns Really That Great?1 month ago | Simply Wall St
Is Fresenius Medical Care KGaA (ETR:FME) Using Too Much Debt?Valuation
Is Fresenius Medical Care KGaA undervalued compared to its fair value and its price relative to the market?
30.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: FME (€67.24) is trading below our estimate of fair value (€98.53)
Significantly Below Fair Value: FME is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: FME is good value based on its PE Ratio (16x) compared to the Healthcare industry average (33.8x).
PE vs Market: FME is good value based on its PE Ratio (16x) compared to the German market (20.6x).
Price to Earnings Growth Ratio
PEG Ratio: FME is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: FME is overvalued based on its PB Ratio (1.6x) compared to the DE Healthcare industry average (1.4x).
Next Steps
Future Growth
How is Fresenius Medical Care KGaA forecast to perform in the next 1 to 3 years based on estimates from 22 analysts?
11.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FME's forecast earnings growth (12% per year) is above the savings rate (-0.4%).
Earnings vs Market: FME's earnings (12% per year) are forecast to grow slower than the German market (13.2% per year).
High Growth Earnings: FME's earnings are forecast to grow, but not significantly.
Revenue vs Market: FME's revenue (6.2% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: FME's revenue (6.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FME's Return on Equity is forecast to be low in 3 years time (12.2%).
Next Steps
Past Performance
How has Fresenius Medical Care KGaA performed over the past 5 years?
15.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FME has high quality earnings.
Growing Profit Margin: FME's current net profit margins (7.5%) are lower than last year (11.7%).
Past Earnings Growth Analysis
Earnings Trend: FME's earnings have grown by 15.2% per year over the past 5 years.
Accelerating Growth: FME's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: FME had negative earnings growth (-34.3%) over the past year, making it difficult to compare to the Healthcare industry average (-6.8%).
Return on Equity
High ROE: FME's Return on Equity (11.3%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Fresenius Medical Care KGaA's financial position?
Financial Position Analysis
Short Term Liabilities: FME's short term assets (€7.2B) do not cover its short term liabilities (€7.4B).
Long Term Liabilities: FME's short term assets (€7.2B) do not cover its long term liabilities (€12.2B).
Debt to Equity History and Analysis
Debt Level: FME's debt to equity ratio (66.6%) is considered high.
Reducing Debt: FME's debt to equity ratio has reduced from 86.2% to 66.6% over the past 5 years.
Debt Coverage: FME's debt is well covered by operating cash flow (27.6%).
Interest Coverage: FME's interest payments on its debt are well covered by EBIT (5.7x coverage).
Balance Sheet
Inventory Level: FME has a high level of physical assets or inventory.
Debt Coverage by Assets: FME's debt is not covered by short term assets (assets are 0.8x debt).
Next Steps
Dividend
What is Fresenius Medical Care KGaA's current dividend yield, its reliability and sustainability?
1.67%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: FME's dividend (1.74%) is higher than the bottom 25% of dividend payers in the German market (1.38%).
High Dividend: FME's dividend (1.74%) is low compared to the top 25% of dividend payers in the German market (3.53%).
Stability and Growth of Payments
Stable Dividend: FME's dividends per share have been stable in the past 10 years.
Growing Dividend: FME's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (27.8%), FME's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: FME's dividends in 3 years are forecast to be well covered by earnings (25% payout ratio).
Next Steps
Management
What is the CEO of Fresenius Medical Care KGaA's salary, the management and board of directors tenure and is there insider trading?
3.8yrs
Average management tenure
CEO
Rice Powell (64yo)
7yrs
Tenure
€6,625,000
Compensation
Mr. Robert Maurice Powell, Jr., also known as Rice, has been the Chief Executive Officer and Chairman of Management at Fresenius Medical Care Management AG, General Partner of Fresenius Medical Care AG & C ...
CEO Compensation Analysis
Compensation vs Market: Rice's total compensation ($USD7.37M) is above average for companies of similar size in the German market ($USD4.52M).
Compensation vs Earnings: Rice's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.8yrs
Average Tenure
58yo
Average Age
Experienced Management: FME's management team is considered experienced (3.8 years average tenure).
Board Age and Tenure
1.7yrs
Average Tenure
70yo
Average Age
Experienced Board: FME's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Franklin Maddux (62yo)
Global Chief Medical Officer & Member of Management board
Rice Powell (64yo)
Chairman of the Management Board & CEO of Fresenius Medical Care Mgmt AG
- Tenure: 7yrs
- Compensation: €6.63m
Kent Wanzek (60yo)
CEO of Global Mfg
- Tenure: 10yrs
- Compensation: €3.04m
Borries Muller (58yo)
Senior Vice President of Global Human Resources Employee Communications
Harry de Wit (57yo)
CEO of APAC & Member of Management Board - Fresenius Medical Care Mgmt AG
- Tenure: 3.8yrs
- Compensation: €2.66m
Olaf Schermeier (47yo)
CEO of Global R&D and Member of the Management Board - Fresenius Medical Care Mgmt AG
- Tenure: 6.8yrs
- Compensation: €2.70m
Bill Valle (59yo)
CEO of North America & Member of Management Board at Fresenius Medical Care Mgmt AG
- Tenure: 3yrs
- Compensation: €3.83m
Dominik Heger
Executive VP and Head of Investor Relations
Katarzyna Mazur-Hofsäß (56yo)
CEO for EMEA & Member of Management Board - Fresenius Medical Care Mgmt AG
- Tenure: 1.3yrs
- Compensation: €2.79m
Helen Giza (51yo)
CFO & Member of Management Board
- Tenure: 0.2yrs
Board Members
Ben Lipps (79yo)
Honorary Chairman of Supervisory Board
- Tenure: 3.5yrs
Rolf Classon (74yo)
Vice Chairman of Supervisory Board
- Tenure: 1.2yrs
- Compensation: €305.00k
Dieter Schenk (66yo)
Chairman of Supervisory Board
- Tenure: 1.7yrs
- Compensation: €296.00k
William Johnston (74yo)
Member of Supervisory Board
- Tenure: 13.7yrs
- Compensation: €300.00k
Gregor Zünd (59yo)
Member of Supervisory Board
- Tenure: 1.3yrs
- Compensation: €25.00k
Pascale Witz (52yo)
Member of Supervisory Board
- Tenure: 3.7yrs
- Compensation: €143.00k
Dorothea Wenzel
Member of Supervisory Board
- Tenure: 0.7yrs
Company Information
Fresenius Medical Care AG & Co. KGaA's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Fresenius Medical Care AG & Co. KGaA
- Ticker: FME
- Exchange: XTRA
- Founded: 1996
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: €20.863b
- Shares outstanding: 298.13m
- Website: https://www.freseniusmedicalcare.com
Number of Employees
Location
- Fresenius Medical Care AG & Co. KGaA
- Else-Kröner Strasse 1
- Bad Homburg
- Hessen
- 61352
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| FMS | NYSE (New York Stock Exchange) | SPONSORED ADR | US | USD | Sep 1996 | |
| FMEA | DB (Deutsche Boerse AG) | SPONSORED ADR | DE | EUR | Sep 1996 | |
| FME | BIT (Borsa Italiana) | Yes | Ordinary Shares | IT | EUR | Oct 1996 |
| FME | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Oct 1996 |
| 0H9X | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Oct 1996 |
| FMCQ.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Oct 1996 |
| FMED | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Oct 1996 |
| FME | WBAG (Wiener Boerse AG) | Yes | Ordinary Shares | AT | EUR | Oct 1996 |
| FME N | BMV (Bolsa Mexicana de Valores) | Yes | Ordinary Shares | MX | MXN | Oct 1996 |
| FME | SWX (SIX Swiss Exchange) | Yes | Ordinary Shares | CH | CHF | Oct 1996 |
| FME | XTRA (XETRA Trading Platform) | Yes | Ordinary Shares | DE | EUR | Oct 1996 |
Biography
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2018, it operated 3,928 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/23 21:12 |
| End of Day Share Price | 2020/01/23 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.